Walgreens Boots Alliance Inc (WBA) reported its Q3 2024 results, reflecting a mixed performance amid persistent challenges in the U.S. retail pharmacy sector. The company achieved revenue of $36.35 billion, up 2.5% year-over-year, but saw a stark decline in profitability, with adjusted EPS dropping 37% to $0.63. Key issues highlighted by management include a challenging consumer environment, reimbursement pressures in the pharmacy sector, and an overall shift in retail dynamics impacting cash flow. Nonetheless, strength in the U.S. healthcare segment and international sales demonstrated resilience, suggesting potential paths to recovery if new strategies are effectively executed. Management has emphasized their commitment to enhancing operational efficiency and redefining the consumer pharmacy experience, which may yield long-term benefits.